Gastroenterology & Family Medicine & Clinical Biochemistry
GGT (gamma-glutamyl transferase)
Gamma-glutamyl transferase (GGT), also known as gamma-glutamyl transpeptidase (GGTP), is a membrane-bound enzyme found mainly in biliary epithelial cells, hepatocytes, renal tubules, pancreas and small intestine. It catalyzes the transfer of the gamma-glutamyl group from peptides to amino acid acceptors - playing a key role in glutathione metabolism and amino acid transport across cell membranes. In clinical practice, GGT is primarily a marker of hepatic cytolysis and cholestasis, but also a sensitive - if unspecific - indicator of alcohol consumption and drug enzyme induction. Isolated elevation, without abnormalities in other liver enzymes (ALT, ASAT, alkaline phosphatases, bilirubin), is one of the most frequent situations encountered in family medicine: it requires a structured diagnostic approach to identify the cause - alcohol, medication, non-alcoholic fatty liver (NAFLD), or occult biliary pathology - and avoid excessive investigation or, conversely, misrecognition of significant liver disease. Reference values vary according to laboratory and gender: generally <55 U/L in men and <38 U/L in women, with significant physiological variability linked to age, body mass index and alcohol consumption.
Biochemistry, reference values and sources of elevation
- Biochemistry and tissue localization of GGT : glycoprotein membrane enzyme of the transpeptidase family - located on the outer side of the epithelial cell plasma membrane - catalyzes the reaction: γ-glutamyl-peptide + amino acid → peptide + γ-glutamyl-amino acid - main physiological role : metabolism of glutathione (antioxidant tripeptide) → GGT cleaves extracellular glutathione to allow recovery of cysteine (limiting amino acid for intracellular glutathione synthesis) + transmembrane transport of amino acids (neutral amino acid mechanism); tissue localization in order of clinical importance: kidney (proximal tubules - highest concentration in the whole body, but urinary GGT does not contribute to serum elevation) + liver (bile duct epithelial cells ++ + hepatocytes - main source of serum GGT) + pancreas + small intestine + brain + heart + lungs → serum GGT mainly reflects hepatobiliary activity; serum half-life: 14-26 days → elevation persists several weeks after cessation of cause (ex: alcohol cessation → normalization in 4-6 weeks); reference values (variable according to automatons and laboratories - check the reference intervals of the laboratory used): man: 10-55 U/L + woman: 7-38 U/L → GGT is physiologically higher in men than in women (androgenic influence on enzyme expression) → increases physiologically with age + BMI + alcohol consumption (dose-dependent effect); GGT elevation - clinical gradation: slight elevation (<3× LSN — limite supérieure de la normale) : cause la plus fréquente — alcool + médicaments + stéatose + obésité + diabète + élévation modérée (3–10× LSN) : cholestase partielle + hépatite virale chronique + cirrhose débutante + infiltration tumorale + élévation importante (>10× LSN): severe cholestasis (complete biliary obstruction + primary biliary cirrhosis + primary sclerosing cholangitis) + severe alcoholic hepatitis + hepatocellular carcinoma or liver metastases
- Causes of GGT elevation - classification by mechanism : enzyme induction (most frequent mechanism of isolated elevation): alcohol is the main inducer of hepatic GGT - mechanism: transcriptional induction of the GGT gene by acetaldehyde (ethanol metabolite) + hepatic oxidative stress + increased de novo GGT synthesis in hepatocytes - characteristics: GGT often disproportionately elevated compared with other liver enzymes (ALAT + ASAT) + ASAT/ALAT ratio often >2 in alcoholic disease (vs. <1 in non-alcoholic hepatitis) + normalization in 4-6 weeks of abstinence → GGT used in practice as an indirect marker of alcohol consumption (sensitivity 52-94 % + specificity 55-84 % for excessive consumption) - drugs inducing hepatic cytochrome P450 → parallel induction of GGT: phenytoin (Dilantin) + carbamazepine (Tegretol) + phenobarbital + rifampicin + griseofulvin + alcohol → GGT is often the only hepatic marker elevated under antiepileptic inducers (asymptomatic elevation + non-toxic in the majority of cases); cholestasis (biliary obstruction - intra- or extrahepatic): mechanism: accumulation of bile acids → induction of GGT in biliary epithelial cells + regurgitation of GGT into circulation → elevated GGT parallels alkaline phosphatases (ALPs) in cholestasis - elevated GGT/PAL ratio points to biliary cholestasis - extrahepatic cholestasis: choledocholithiasis + pancreatic cancer + biliary tract cancer (cholangiocarcinoma) + post-surgical biliary stenosis + parasites (roundworm + echinococcus) - intrahepatic cholestasis : primary biliary cirrhosis (PBC - anti-mitochondrial antibodies AMA) + primary sclerosing cholangitis (PSC - IBD ++) + drug-induced cholestasis (amoxicillin-clavulanate ++ + co-trimoxazole + chlorpromazine + estrogens) + hepatic sarcoidosis + lymphoma; non-alcoholic hepatic steatosis (NAHS - MASLD - Metabolic-Associated Steatotic Liver Disease): mechanism: lobular inflammation + mitochondrial oxidative stress → GGT induction - SHNA = increasing cause of elevated GGT in the context of the obesity epidemic and type 2 diabetes - elevated GGT in 40-80 % of SHNA + moderate elevation (1-3× ULN usually) + often associated with elevated ALAT; hepatic cytolysis (acute or chronic hepatitis): viral hepatitis (B + C + E) + autoimmune hepatitis + drug-induced hepatitis (DILI) + ischemic hepatitis (liver shock) + cirrhosis - GGT variably elevated → interpretation with clinical context and other enzymes; extrahepatic diseases: congestive heart failure (hepatic congestion → congestive hepatopathy → elevated GGT ± alkaline phosphatases ± bilirubin) + hyperthyroidism (enzyme induction) + type 2 diabetes (insulin resistance + steatosis) + obesity (BMI ≥30 → GGT elevated in a dose-dependent manner) + metabolic syndrome
- Diagnostic value and limitations of GGT : strengths of GGT as a clinical marker : very sensitive for detecting hepatobiliary pathology (sensitivity 80-90 % for liver disease in general) + early marker of cholestasis (often elevated before alkaline phosphatases in early biliary obstructions) + marker of alcohol consumption (used in occupational medicine + fitness assessments) + cardiovascular and metabolic prognostic marker (longitudinal epidemiological studies - GGT in the high part of the normal range → increased risk of diabetes + metabolic syndrome + cardiovascular events - Meisinger 2006 + Ruttmann 2005) ; limitations of GGT : highly unspecific (can be elevated in dozens of conditions - hepatic and extrahepatic) + cannot distinguish the cause of liver damage on its own + physiological elevation in pregnant women (3rd trimester - GGT often >2× ULN without pathology) + significant intra-individual variation (20-40 %) depending on time of sampling + nutritional status + recent alcohol intake → GGT should never be interpreted in isolation - always place it in the clinical context and in association with other liver markers (ALT + ASAT + PAL + bilirubin + TP); situations where GGT is normal despite liver pathology: early acute viral hepatitis (GGT may be normal in early infection) + early hepatic fibrosis without active inflammation + isolated hepatic steatosis without inflammation (simple steatosis - MAFL without MASH)
Diagnostic approach, interpretation and management
| Clinical situation | Interpretation and balance sheet | Procedure and follow-up |
|---|---|---|
| Isolated elevated GGT (<3× LSN) - liver function tests otherwise normal Alcohol - drugs - steatosis - obesity |
Isolated slightly elevated GGT with an otherwise normal liver workup (normal ALAT + ASAT + PAL + bilirubin) is the most frequent situation in family medicine - it requires a structured clinical approach; first step - targeted questioning: alcohol consumption (quantify in standard units - 1 standard glass = 13.6 g pure alcohol in Canada) → validated questionnaires: AUDIT-C (3 questions - sensitivity 73-86 % for at-risk consumption) or CAGE (Cut - Annoyed - Guilty - Eye opener) → an AUDIT-C score ≥3 in women and ≥4 in men is positive for at-risk consumption + drugs and natural products: antiepileptic inducers (phenytoin + carbamazepine + phenobarbital) + statins (frequent cause of mild elevation of transaminases and GGT) + anti-TB (rifampicin) + hepatotoxic natural health products (kava + valerian + concentrated green tea + germander + chaparral) → an exhaustive list of drugs should be reviewed + BMI + waist circumference (metabolic steatosis) + symptoms of diabetes + metabolic syndrome + family history of liver disease ; second step - complementary work-up : fasting blood glucose + HbA1c (diabetes + insulin resistance) + lipidogram (dyslipidemia + metabolic syndrome) + TSH (hyperthyroidism) + CBC (macrocytosis high VGM → chronic alcohol consumption + folate deficiency) + CDT (carbohydrate-deficient transferrin) : biochemical marker of chronic alcohol consumption - specificity 90-95 % for consumption >60 g/d × ≥2 weeks → more specific than GGT alone for the diagnosis of alcohol dependence - assay available in Quebec reference laboratories (CHU + CISSS + CIUSSS) + abdominal ultrasound: search for hepatic steatosis (hyperechoic echostructure of the liver) + biliary tract dilatation + vesicular lithiasis + hepatic mass → non-irradiating + inexpensive 1st-line examination | Conduct according to clinical orientation: elevated GGT + significant alcohol consumption identified: minimal counseling (brief intervention) + present health risk associated with consumption → repeat GGT assay + CBC + ALAT + ASAT after 4-6 weeks of abstinence → if normalization → alcohol confirmed as cause → follow-up and support → if not normalization despite abstinence → explore other causes + elevated GGT + inducing drug identified (carbamazepine + phenytoin ++): if elevation 3× LSN or ALAT elevated → discuss with prescribing physician → possible substitution + elevated GGT + steatosis on ultrasound + metabolic syndrome: diagnosis of metabolic hepatic steatosis (MASLD) → hygienic-dietary measures (weight loss 7-10 % → significant reduction in liver enzymes and steatosis) + glycemic control + physical activity 150 min/week → reassessment at 3-6 months → if abnormalities persist despite measures → referral to gastroenterology/hepatology + isolated elevated GGT without identified cause after 1st-line workup: clinical + biological monitoring at 6-12 months + repeat ultrasound → no systematic invasive investigation (liver biopsy) for mild isolated GGT without signs of advanced liver disease |
| Elevated GGT + elevated alkaline phosphatase (ALP) Cholestasis - biliary tract - imaging |
The concomitant elevation of GGT and alkaline phosphatases (ALP) is the biological profile of cholestasis - it points to intra- or extrahepatic bile duct obstruction; interpretation of the GGT + elevated ALP profile: confirmation of the hepatic origin of the elevated ALP: if PAL elevated + GGT elevated → hepatobiliary origin confirmed (PAL may be elevated of bone + placental + intestinal origin → GGT confirms hepatic origin, as it is not elevated in extrahepatic causes of PAL). extrahepatic causes of PAL) → if PAL elevated + GGT normal → probable bone origin (Paget's disease + osteomalacia + bone metastases + hyperparathyroidism) → assay bone fraction of PAL or bone markers (osteocalcin + CTX) ; biochemical profile of cholestasis: GGT + PAL very elevated (5-20× LSN) + conjugated bilirubin elevated (cholestatic jaundice) + ALAT + ASAT normal or moderately elevated → pure cholestasis (biliary obstruction) + GGT + PAL + ALAT + ASAT all elevated → cholestatic hepatitis (drug-induced hepatitis ++ + viral hepatitis + autoimmune hepatitis); cholestasis workup - 1st-line imaging: abdominal ultrasound : 1st examination - dilatation of intra- or extrahepatic bile ducts → biliary obstruction → identify vesicular lithiasis + choledochal calculi (acoustic shadow) + pancreatic mass + choledochal dilatation - sensitivity 90 % for biliary dilatation - lower sensitivity for choledochal calculi (50-70 %) ; direct + indirect bilirubin + PT + albumin (evaluation of synthetic liver function) + hepatitis A + B + C serologies (if undocumented) + anti-mitochondrial antibodies (AMA) : if chronic unobstructed intrahepatic cholestasis → primary biliary cirrhosis (PBC - formerly PBC) → AMA positive in 95 % of PBCs + elevated IgM + anti-smooth muscle antibodies (ASMA) + ANA: if cholestasis + hepatitis → autoimmune hepatitis or PBC/HAI overlap + pANCA + ASCA: if cholestasis + IBD → primary sclerosing cholangitis (PSC) | Advanced imaging and management of cholestasis: if ultrasound shows bile duct dilatation with no obvious cause (calculus not visualized) → cholangio-MRI (MRCP - Magnetic Resonance Cholangiopancreatography): 2nd reference examination - non-invasive visualization of bile + pancreatic ducts - sensitivity 90-95 % for choledocholithiasis + 85-90 % for cholangiocarcinoma → ideal before any therapeutic decision + abdominal CT scan with contrast: if suspicion of pancreatic or tumoral mass + lymph node extension → often complementary to cholangio-MRI + echoendoscopy (EUS - endoscopic ultrasound): if diagnostic doubt persists after cholangio-MRI → direct visualization of papilla + distal bile ducts + pancreatic parenchyma - sensitivity 95 % for choledocholithiasis + guided biopsy possible if mass + ERCP (endoscopic retrograde cholangiopancreatography): for therapeutic purposes (stone extraction + biliary prosthesis) - not 1st diagnostic intention since the advent of cholangio-MRI; main causes according to clinical profile: elevated GGT + PAL + jaundice + radiating bar pain + weight loss → pancreatic cancer → CT + CA 19-9 + urgent onco-surgical advice + elevated GGT + PAL + typical biliary pain (right shoulder + scapular irradiation) + fever (cholangitis) → choledocholithiasis + acute Charcot cholangitis → urgent therapeutic ERCP + IV antibiotic therapy + elevated GGT + PAL + IBD (Crohn's + UC) + chronic cholestasis → CSP → cholangio-MRI → hepatology advice → liver transplantation (only curative treatment) + elevated GGT + PAL + middle-aged woman + pruritus + asthenia + positive AMA → PBC → ursodeoxycholic acid (AUDC) 13-15 mg/kg/d → slows progression → hepatology advice |
| Elevated GGT + elevated ALT + ASAT (hepatic cytolysis) Hepatitis - DILI - alcoholic hepatitis - fibrosis |
Concomitant elevation of GGT and transaminases (ALAT + ASAT) defines a hepatic cytolysis profile with enzyme induction - the picture points to acute or chronic hepatitis; interpretation of the ASAT/ALAT ratio (de Ritis): ASAT/ALAT ratio >2 (ideally >3): highly suggestive of alcoholic hepatopathy (alcohol preferentially alters hepatic mitochondria - site of mitochondrial ASAT) + in alcoholic hepatitis: ASAT rarely >300 U/L (even in severe forms - characteristic) + ASAT/ALAT ratio 1 with ALAT >10× LSN: acute hepatitis (viral A + toxic + ischemic) → diagnostic urgency; etiological work-up of cytolysis GGT + transaminases: viral hepatitis serologies: HBsAg + anti-HBc IgM + anti-HBs (hepatitis B) + anti-HCV + HCV RNA if anti-HCV positive (hepatitis C) + anti-HAV IgM (acute hepatitis A) + anti-HEC IgM (hepatitis E - traveler + pig) + autoimmune work-up: ANA + ASMA + anti-LKM1 + anti-SLA + total IgG (autoimmune hepatitis) + metabolic work-up: ferritin + transferrin saturation (hemochromatosis) + ceruloplasmin + 24h urinary copper (Wilson - young adult + neuropsychiatric) + alpha-1-antitrypsin (deficiency - associated emphysema) + echoFibroscan (liver elastometry) or FibroTest: non-invasive evaluation of liver fibrosis - avoids biopsy in most cases - indicated if confirmed chronic hepatitis (HCV + HBV + MASH) → stage F0-F4 (METAVIR) | Acute alcoholic hepatitis - specific management: clinical picture: ASAT 2-10× LSN + ASAT/ALAT ratio >2 + very high GGT + high bilirubin + prolonged PT + fever + painful hepatomegaly + AGA (possible encephalopathy) + after recent massive alcohol consumption → Maddrey score (discriminant function): 4.6 × (patient TP - control TP) + bilirubin (µmol/L)/17.1 → if ≥32 → severe alcoholic hepatitis → 30-day mortality: 30-50 % without treatment → treatment: prednisolone 40 mg/d × 28 days (reduced mortality at 28 days: NNT = 5 - STOPAH 2015 trial - NEJM) + pentoxifylline: no additional benefit vs prednisolone in STOPAH + absolute alcohol abstinence + enteral nutrition + prevent and treat hepatic encephalopathy (lactulose + rifaximin) + infections (increased susceptibility); LILLE score (at D7 on corticosteroids): if bilirubin does not decrease at D7 → LILLE score ≥0.45 → poor responder to corticosteroids → corticosteroids discontinued → early liver transplantation discussed (some centers - strict patient selection); drug-induced hepatitis (DILI - Drug-Induced Liver Injury): to be evoked systematically in the presence of any recent-onset cytolysis + elevated GGT → exhaustive review of drugs (prescription + self-medication + phytotherapy + dietary supplements) → time to onset: 5 days to 3 months after introduction → suspect drug discontinued → progressive normalization → in case of doubt: LiverTox (NIH online database) or RUCAM score (assessment of drug-hepatitis causality) → severe drug-induced hepatitis (ALT >10× LSN + jaundice + prolonged PT) → Hy's Law criteria → hospitalization + hepatology opinion + N-acetylcysteine (paracetamol + other severe DILI according to some experts) |
| GGT and alcohol - use in clinical practice Consumption marker - CDT - AUDIT - abstinence monitoring |
GGT is the most widely used biochemical marker for assessing alcohol consumption in clinical practice - although its sensitivity and specificity are imperfect, it remains useful in monitoring abstinence and detecting excessive consumption; diagnostic performance of GGT for alcohol consumption: sensitivity for excessive consumption (>40 g/d): 52-94 % depending on thresholds used + specificity: 55-84 % (many non-alcoholic causes of elevation) + positive predictive value: low in general population (lack of specificity) → GGT alone is insufficient to affirm an alcohol-related disorder → always supplement with structured questioning (AUDIT-C or CAGE); combination GGT + CDT (carbohydrate-deficient transferrin): CDT : marker of abnormal transferrin glycosylation induced by chronic alcohol consumption (>60 g/d × ≥2 weeks) - specificity 90-95 % + sensitivity 40-70 % - less sensitive than GGT but much more specific - used in occupational medicine (driving GGT + CDT combined → sensitivity 75-90 % for severe alcohol use disorder - recommended together in the assessment of abstinence in driver's license withdrawal programs (SAAQ in Quebec); GGT kinetics under abstinence : GGT half-life: 14-26 days → after complete abstinence: reduction of 50 % in 2-3 weeks → complete normalization in 4-8 weeks if the only cause was alcohol → if no normalization at 8 weeks of verified abstinence → look for another cause (steatosis + medication + biliary pathology); VGM (mean corpuscular volume - macrocytosis): marker of chronic alcoholism + folate/B12 deficiency - sensitivity 50-60 % - longer half-life than GGT (normalization in 3-6 months) → less useful for short-term monitoring than GGT + CDT | Use of GGT in the follow-up of alcohol use disorder (AUDIT): role of the family doctor: systematic AUDIT screening → AUDIT-C at each annual check-up (MSSS Quebec + PHAC recommendations) → if AUDIT-C positive → brief motivational intervention (5 minutes - proven efficacy in reducing consumption - Moyer 2002) → GGT assay (+ CDT if available) as objective marker for follow-up → reassessment at 4-8 weeks; biological follow-up of abstinent or reduced consumption patient: GGT + CBC + VGM + ALAT at initiation + at 4-8 weeks (confirmation of normalization or reduction) → document evolution in the medical record → use GGT trend (gradual decrease) as a motivational tool for the patient (objective positive reinforcement); referral to specialized resources: if severe AHT or confirmed dependence → referral to a specialized resource: Centre de réadaptation en dépendance (CRD - CISSS/CIUSSS in Quebec) + medicalized detoxification program if withdrawal syndrome expected (tremor + anxiety + risk of delirium tremens) → benzodiazepines (diazepam + lorazepam) + IV thiamine (Wernicke) + telephone line: 1 866 APPELLE (277-3553) in Quebec (MSSS - addiction helpline); GGT in advanced hepatic fibrosis (cirrhosis): in advanced alcoholic cirrhosis + PBC + PSC: chronically very high GGT → prognostic marker (independent prognostic value in several cohort studies) → in cirrhosis, GGT may paradoxically normalize in terminal phase (severe hepatocellular failure → loss of GGT-producing cells) |
| GGT as a marker of cardiovascular and metabolic risk Steatosis - metabolic syndrome - CV risk - MASLD |
Beyond its role as a hepatobiliary marker, GGT has been identified as an independent marker of cardiovascular and metabolic risk in several large prospective epidemiological studies; epidemiological data - GGT and cardiovascular risk: Vorarlberg study (Ruttmann 2005 - European Heart Journal - 163,944 participants + 17-year follow-up): GGT in upper quartile of normal → cardiovascular mortality risk increased by 50-70 % after adjustment for confounding factors → association persists even for GGT values in upper normal range (20-40 U/L) → suggests that GGT reflects underlying systemic oxidative stress + meta-analysis (Fraser 2007 - Lancet): elevated GGT → risk of type 2 diabetes increased by 70-80 % → proposed mechanism: glutathione depletion (oxidative stress) → mitochondrial dysfunction → insulin resistance → GGT could be an early marker of transition to diabetes; MASLD (Metabolic-Associated Steatotic Liver Disease - formerly NAFLD/NASH) and GGT: MASLD = most frequent liver disease in Western countries (prevalence 25-30 % of adult population) + risk factors: obesity + T2DM + dyslipidemia + hypertension + metabolic syndrome - elevated GGT in 40-80 % of MASLD - marker of progression (simple steatosis → steatohepatitis - MASH → fibrosis → cirrhosis) - GGT + ALAT + AST → FIB-4 score (Fibrosis-4 Index) : formula = (age × ASAT) / (platelets × square root of ALAT) → if FIB-4 2.67 → advanced fibrosis likely (PPV 80 %) → FIB-4 recommended by AASLD + EASL guidelines as a non-invasive fibrosis triage tool in MASH + liver elastometry (FibroScan): if FIB-4 intermediate or high → liver stiffness measurement → E >9-10 kPa → significant fibrosis → gastroenterology/hepatology opinion | Management of MASLD with elevated GGT: no drugs specifically approved for MASLD in Canada in 2025 (clinical trial results pending) → treatment based on lifestyle modifications; weight loss: target 7-10 % of body weight → reduction in hepatic steatosis + inflammation (MASH) + fibrosis → normalization or significant reduction in liver enzymes (ALAT + GGT) in 80 % of cases → recommendations: hypocaloric diet (500-1,000 kcal/d deficit) + aerobic physical activity 150 min/week (moderate intensity) + reduction of refined carbohydrates + added sugars (fructose ++) + Mediterranean diet → solid data for reducing steatosis and inflammation; GLP-1 agonists (semaglutide + liraglutide): significant reduction in steatosis + inflammation in clinical trials (LEAN - NEJM 2016 + NASH) → promising data for MASH with fibrosis → awaiting specific approval in MASH + indication already available for T2DM + obesity → off-label use questionable in the absence of formal approval for MASH; resmetirom (Rezdiffra): selective thyroid hormone receptor beta (THR-β) agonist - FDA approved March 2024 for MASH with F2-F3 fibrosis - MAESTRO-NASH trial - submitted to Health Canada → availability to be monitored in Canada + vitamin E (800 IU/d): antioxidant - reduced MASH activity in non-diabetic adults (PIVENS - NEJM 2010) → option in non-diabetic adults with histologically confirmed MASH → not recommended in diabetics (conflicting studies on cardiovascular risk); GGT monitoring in MASH: GGT + ALAT + CBC + blood glucose + lipidogram → every 6-12 months + FIB-4 annually → if progression → FibroScan → if F3-F4 → hepatology referral |
ℹ️
Isolated slightly elevated GGT does not warrant invasive investigation: a GGT between 1 and 3 times the upper limit of normal, with an otherwise strictly normal liver work-up, does not require systematic liver biopsy. The initial approach is based on questioning (alcohol, medication, herbal medicine), BMI, blood glucose and abdominal ultrasound. In most cases, the cause is identifiable - alcohol, metabolic steatosis, inducing medication - and can be managed by simple measures. Biological follow-up at 3-6 months confirms stability or resolution of abnormalities.
Situations requiring urgent medical assessment
GGT + ALAT + ASAT very high (>10× LSN) + jaundice + prolonged PT + encephalopathy → acute liver failure (fulminant hepatitis - drug-induced, viral, severe alcoholic) → urgent hospitalization + hepatology opinion + evaluation for emergency liver transplantation.
Elevated GGT + PAL + jaundice + biliary pain + fever + chills (Charcot's triad) → acute bacterial cholangitis on choledocholithiasis → emergency - therapeutic ERCP + broad-spectrum IV antibiotic therapy (piperacillin-tazobactam or cefotaxime + metronidazole) + hospitalization.
Elevated GGT + unintentional weight loss + epigastric pain radiating to the back + progressive jaundice without biliary pain in a patient >50 years old → pancreatic cancer to be excluded → thoraco-abdomino-pelvic CT scan with contrast + CA 19-9 + urgent surgical opinion.
GGT + elevated transaminases + jaundice + fever + recent use of a new drug or herbal medicine → severe drug-induced hepatitis (DILI) → immediate discontinuation of suspect drug + hospitalization if Hy's Law criteria (ALT >3× LSN + bilirubin >2× LSN) → N-acetylcysteine + hepatology opinion.
Consult at Clinique Omicron
Clinique Omicron's physicians interpret abnormal liver function tests, including GGT, in their overall clinical context - assessing alcohol consumption, identifying inducing medications, screening for metabolic steatosis, and referring to gastroenterology or hepatology when necessary. These consultations are available at several points of service in Quebec, as well as via telemedicine. To book an appointment, visit cliniqueomicron.ca.
The content of this page is provided for information purposes only and does not replace the advice of a physician or gastroenterologist. Any persistent liver abnormality should be evaluated by a healthcare professional to identify the cause and guide appropriate management.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.